Humira Safe and Effective for up to Six Years in Crohn’s Disease Patients, Study Shows

Humira Safe and Effective for up to Six Years in Crohn’s Disease Patients, Study Shows
Humira (adalimumab) is safe and effective for Crohn's disease (CD) patients for up to six years when used in routine clinical practice, a study suggests. The study, "Adalimumab Effectiveness Up to Six Years in Adalimumab-naïve Patients with Crohn’s Disease: Results of the PYRAMID Registry," was published in the journal Inflammatory Bowel Diseases. Humira is a biological therapy manufactured by AbbVie, approved by the U.S. Food and Drug Administration for the treatment of inflammatory bowel disease (IBD). It was approved to treat Crohn's in 2007 and ulcerative colitis in 2012. The therapy consists of an antibody that specifically binds and blocks an inflammatory protein called tumor necrosis factor alpha or TNFa. Blocking TNFa reduces inflammation and consequently IBD symptoms. Humira induced remission in CD patients in different clinical trials, and various studies have shown that it is safe and effective when used for up to four years. The international Pyramid registry (NCT00524537) assessed the long-term safety of Humira use in clinical practice, according to the specifications of the product label, in different countries where t
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *